Cell therapies for refractory rheumatoid arthritis

Clin Exp Rheumatol. Sep-Oct 2018;36(5):911-919. Epub 2018 May 8.

Abstract

Rheumatoid arthritis (RA), an autoimmune disease, is characterised by a persistent synovitis in the joints and systemic inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease-modifying antirheumatic drugs (DMARDs) are widely used to treat RA patients. However, a portion of patients still have inadequate response to traditional medications. Recently, cell-based therapies have become the focus, attracting more attention due to their potential for remission induction. Several immune-regulatory cell types, such as haematopoietic stem cells, mesenchymal stem cells and regulatory T cells have been defined as novel targets. In this paper, we have summarised and reviewed current clinical trials using cell-based therapeutic approaches for the treatment of RA.

Publication types

  • Review

MeSH terms

  • Animals
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / diagnosis
  • Arthritis, Rheumatoid / immunology
  • Arthritis, Rheumatoid / therapy*
  • Cell- and Tissue-Based Therapy / adverse effects
  • Cell- and Tissue-Based Therapy / methods*
  • Drug Resistance
  • Humans
  • Remission Induction
  • Treatment Outcome

Substances

  • Antirheumatic Agents